Coriolis Pharma is a science-driven, globally operating contract research and development organization (CRDO) supporting drug product development of biopharmaceuticals, including cell and gene therapies and vaccines.

Its focus lies on formulation development, lyphilizatiuon technologies and analytics (GMP and non-GMP). It is the vision of Coriolis to revolutionize the development process of biopharmaceutical drugs by integrating innovative digital formulation approaches from drug development to commercial products.

With its interdisciplinary team of highly skilled scientists and an expert scientific advisory board, Coriolis provides cutting-edge services and tailor-made solutions for its clients.

Coriolis was founded in 2008 and currently employs more than 200 employees from over 36 nations around the world. For more information visit www.coriolis-pharma.com.